price target, page-25

Nice find. When I look at the possibilities ahead, I am getting more and more convinced we should go it alone for Phase 3 and subsequently license the drug. At close to $1B MC, we can afford to raise for a $200M trial. It appears we have some strong support from a few funds who continue to buy up at these levels and would happily open up the purse strings for a potential 5-Disallowed from here.